Comprehensive Study Notes on General and Clinical Pharmacology
Scope and Foundations of Pharmacology
Curriculum Organization & Study Units:
- Unit I: General Pharmacology.
- Unit II: Autonomic Nervous System (ANS), comprising the Sympathetic and Parasympathetic nervous systems.
- Unit III: Central Nervous System (CNS).
- Unit 4: Body Systems.
- Unit V: Chemotherapy.
- Unit 6: Toxicology.
Fundamental Definitions & Etymology:
- Pharmacology: Derived from the Greek roots Pharmakon (meaning drug or medicine) and logos (meaning study or science). It is defined as the science or experimental study of drugs and medicines, dealing comprehensively with the properties of drugs and their actions and effects on living biological systems.
- Medical Aphorism: "All medicines are drugs, but all drugs are not medicines."
- Drug (Etymology & Concept): Derived literally from the French word drogue (signifying dry herb). A drug is defined as any chemical substance used for the diagnosis, mitigation, prevention, and treatment of disease in humans and animals, aimed at decreasing pain and eradicating pathology.
- World Health Organization (WHO) Definition of a Drug: Any substance or product that is used or intended to be used to modify or explore physiological systems or pathological states for the benefit of the recipient.
Historical Luminaries of Pharmacology:
- Oswald Schmiedeberg: Recognized universally as the Father of Modern Pharmacology.
- L. Meyer Jones: Recognized as the Father of Modern Veterinary Pharmacology.
- Sir Col. Ram Nath Chopra: Recognized as the Father of Indian Pharmacology.
Branches and Terminology of Pharmacology
Core Quantitative Terms:
- Dose: The specified minimum amount of any drug or chemical compound required to produce a desired therapeutic response, bounded between the threshold of therapeutic efficacy and maximum overdose.
- Dosage: The calculated schedule that defines the exact dose, dosing frequency, and duration of treatment. For example:
- Posology: The specialized branch of pharmacology that deals strictly with the study of drug dosage and dosing regimens (the initial "P" is silent in pronunciation).
- Pharmacognosy: The branch of pharmacology that deals with the identification, extraction, and characterization of drugs derived from natural sources (plants, animals, minerals, and microbes).
- Metrology: The science of weights and measures as applied specifically to the preparation, compounding, and clinical administration of pharmacological agents.
- Pharmacy: The comprehensive science and profession dealing with the collection, identification, preparation, standardization, preservation, compounding, and dispensing of medicinal substances.
Specialized Fields of Pharmacology:
- Experimental Pharmacology: The branch devoted to the systematic laboratory investigation and evaluation of drugs in experimental animal models.
- Clinical Pharmacology: The scientific discipline focusing on the evaluation and investigation of drugs directly in human subjects and clinical animal patients.
- Pharmacometrics: A critical branch focusing on the qualitative and quantitative measurement of drug action and responses under strictly controlled laboratory conditions.
- Pharmacogenomics: The branch dealing with the analysis of individual genetic variations and inherited genomic differences that cause variable drug responses across populations.
- Immunopharmacology: The study of pharmacological agents that modulate, stimulate, or suppress the immune system (e.g., immunosuppressants).
- Chemotherapy: The study and clinical use of drugs that selectively destroy or inhibit specific disease-causing microorganisms or cells, including pathogenic bacteria, viruses, fungi, and parasites, with minimal host damage.
- Toxicology: The specialized study of toxins, poisons, their biological manifestations, and their antidotes.
- Pharmacotherapeutics: The application of pharmacological knowledge to the prevention, management, and treatment of pathological conditions and diseases.
- Pharmacoeconomics: The branch evaluating the cost-effectiveness, economic value, and comparative financial benefits of various drug therapy regimens.
- Pharmacoepidemiology: The population-scale study of the utilization, beneficial effects, and adverse outcomes of drugs across large human and animal communities.
- Pharmacovigilance: The clinical science devoted to drug safety monitoring through the systematic detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) and related problems.
- Therapeutics: The broad art and application of all scientific modalities—including surgery, dietary modification, exercise, and drug administration—to the comprehensive cure and management of disease.
Therapeutic Approaches and Classifications
- Therapeutic Methodologies:
- Empirical Therapy: The administration of medicinal agents based solely on clinical experience and empirical observation without scientific validation of the drug's exact mechanism of action or the specific etiology of the disease.
- Rational Therapy (Specific Therapy): The administration of drugs based completely on scientific and pharmacological understanding of the drug's mechanism of action alongside verified pathophysiology of the underlying disease.
- Symptomatic Therapy: Drug therapy directed strictly at alleviating outward clinical symptoms without curing or addressing the underlying disease, administered with or without an established definitive diagnosis (e.g., administering diazepam to control acute epileptic fits/seizures).
- Palliative Therapy: Therapeutic intervention focused on controlling the severity of disease symptoms, decreasing intractable pain, extending survival, and improving quality of life in patients suffering from progressive or terminal conditions (e.g., end-stage cancer management).
- Supportive Therapy: Therapy designed to sustain a patient's vital physiological, functional, and biochemical integrity until self-limiting disease resolves (e.g., intravenous fluid therapy in severe dehydration).
- Replacement Therapy: The clinical administration of substances to replace or supply endogenous biomolecules that the body fails to synthesize in adequate physiological amounts (e.g., insulin in diabetes mellitus, thyroxine, or other hormones).
- Placebo Therapy: The administration of completely inert, pharmacologically harmless substances (such as dextrose or starch) purely for psychological satisfaction and relief of the patient.
Official Compendia and Drug Regulation
Pharmacopoeia Standards:
- Definition: An official legal compendium published by the authority of a recognized national or international government body, containing an exhaustive list of approved drugs along with their physical and chemical properties, standardized purity assays, compounding formulas, and biological criteria.
- Historical Milestones:
- USP (United States Pharmacopeia): First published in the year .
- BP (British Pharmacopoeia): First published in the year .
- IP (Indian Pharmacopoeia): First published in the year .
Over-The-Counter (OTC) Formulations:
- Definition: Pharmaceutical products and medications legally approved for direct sale to consumers without needing a prescription from a licensed healthcare practitioner or veterinarian.
- Examples: Aspirin, non-prescription analgesics, and anti-dandruff shampoos.
Spectrum of Drug Effects and Toxicities
- Definitions of Biological Drug Responses:
- Pharmacological Effects: The physiological, biochemical, and functional changes elicited inside the host body by a drug administered at standard therapeutic doses.
- Adverse Effects: Any undesirable, potentially unavoidable, and noxious drug effect arising during regular clinical administration.
- Side Effects: Inevitable, non-target, undesirable effects produced by standard therapeutic doses of a drug as a direct consequence of its normal pharmacological mechanism of action; they are generally non-fatal and non-detrimental to the immediate survival of the host.
- Toxic Effects: Highly severe, deleterious, and potentially lethal responses that directly impair host survival and normal organ function, demanding immediate therapeutic cessation of the offending compound or urgent medical intervention.
- Transient Effects: Brief, self-limiting pharmacological responses that manifest quickly and resolve shortly after drug delivery (e.g., temporary shivering following rapid intravenous fluid infusion).
- Cumulative Effects: Pathological drug manifestations produced by progressive summation of successive doses, occurring when rate of absorption or administration surpasses systemic elimination and clearance (e.g., accumulation of active aminoglycoside antibiotic metabolites causing nephrotoxicity and ototoxicity).
- Latent Effects: Long-delayed pharmacological or pathological effects where the manifestation occurs extended periods after initiation or cessation of therapy (e.g., delayed development of osteoporosis following prolonged corticosteroid therapy).
Principles of Drug Nomenclature
- Nomenclature Classes:
- Chemical Name: The precise systematic chemical designation assigned strictly based on the molecular and chemical configuration of the drug according to IUPAC nomenclature conventions (e.g., N-acetyl-para-aminophenol).
- Non-Proprietary Name (Generic Name): A standardized, universally recognized official name assigned by international regulatory bodies (such as the WHO) to clearly identify the Active Pharmaceutical Ingredient (API); designed for ease of spelling and verbal pronunciation (e.g., Paracetamol, Amoxicillin).
- Approved Name: The specific generic nomenclature assigned by official regional drug naming committees, such as USAN (United States Adopted Names).
- Official Name: The designated name published within official national pharmacopoeias, derived from the established full chemical designation of the compound.
- Proprietary Name (Brand Name / Trade Name): The exclusive commercial registered trademark given by an individual manufacturing pharmaceutical company for marketing and selling the drug (e.g., Dolo, Crocin for paracetamol).
Sources and Classification of Drugs
- Origin-Based Categorization:
- 1. Natural Sources:
- Organic: Derived from living matter:
- Plants:
- Atropa belladonna: Yields the anticholinergic alkaloid atropine extracted from leaves; utilized as a pre-anaesthetic medication to decrease excessive respiratory and salivary secretions.
- Digitalis purpurea: Yields the cardiac glycoside digitoxin; utilized clinically as a cardiotonic and cardiostimulant.
- Cinchona: Yields the alkaloid quinine extracted from the tree bark; used as an antimalarial agent.
- Clove: Yields eugenol; possesses potent local anesthetic properties highly effective in alleviating dental/tooth pain.
- Asparagus racemosus: Roots yield Shatavari; clinically employed as a galactagogue, for supporting female reproductive health, and maintaining hormonal balance.
- Animals: Yield biological products such as hormones (insulin, thyroid extracts) and serums.
- Microorganisms: Provide natural antimicrobials such as penicillin.
- Inorganic: Comprises earth minerals categorized into metallic sources (e.g., iron, magnesium) and non-metallic sources (e.g., sulfur, iodine).
- 2. Semi-Synthetic Sources:
- Compounds prepared by taking a naturally occurring drug substance and chemically altering its molecular structure in the laboratory to produce improved efficacy, greater potency, altered bioavailability, or lower toxicity compared to the parental molecule.
- Example: Penicillin is chemically modified to synthesize Ampicillin, which demonstrates a broader antimicrobial spectrum and enhanced clinical potency over penicillin.
- 3. Synthetic Sources:
- Compounds manufactured entirely de novo inside laboratory settings from basic chemical reagents without using natural biological templates.
- Examples: Sulphonamides, synthetic corticosteroids, chloroform, and diethyl ether.
Active Principles of Medicinal Plants
Major Bioactive Chemical Classes:
Alkaloids:
Naturally occurring, nitrogenous organic bases possessing alkaline characteristics.
Chemical Reactivity: Combine readily with organic and inorganic acids to synthesize water-soluble salts:
Solubility: Free alkaloids are poorly soluble in water but highly soluble in alcohol; their acid salts reverse this solubility, dissolving readily in water.
Clinical Antidote: Alkaloids form insoluble precipitates in the presence of tannic acid. Therefore, tannic acid serves as a specific chemical antidote used to precipitate alkaloids in the gastrointestinal tract during alkaloid poisoning.
Nomenclature: Chemical names universally terminate with the suffix "-ine" (e.g., Atropine, Morphine, Quinine, Cocaine).
Glycosides:
Non-nitrogenous organic chemical structures that remain neutral in nature.
Neutrality: Do not combine with acids to form salts; dissolve readily in water.
Structural Subunits: Formed by two distinct chemical moieties linked via a glycosidic bond:
- Glycan (Sugar Moiety): Governs physical solubility, tissue permeability, transport, and overall duration of action.
- Aglycone / Genin (Non-Sugar Moiety): Responsible for the core pharmacological and therapeutic activity of the molecule.
Nomenclature: Names generally conclude with the suffix "-in" (e.g., Digitoxin, Digoxin, Gitoxin, Ouabain).
Saponins:
Non-nitrogenous plant glycosides that produce permanent colloidal foam and froth when agitated vigorously in aqueous solutions.
Structure: Composed of a glycone (sugar) joined to an aglycone designated as a sapogenin, which directs the biological and pharmacological response.
Classification: Frequently classified as a functional subclass of glycosides.
Example: Glycyrrhizin.
Resins:
Complex chemical exudates produced in specialized plant secretory duct tissues, formed biochemically by the direct oxidation and polymerization of volatile essential oils.
Resin Subtypes:
- Oleoresins: Natural mixtures consisting of volatile essential oils and resins (e.g., crude turpentine).
- Gum-Resins: Natural mixtures formed of vegetable gums combined with resins (e.g., Asafoetida / Asfoetida).
- Balsams: Aromatic resinous mixtures containing oleoresins chemically combined with benzoic acid, cinnamic acid, or their corresponding esters (e.g., Balsam of Peru).
Tannins:
Non-nitrogenous complex polyphenolic derivatives characterized by powerful astringent action (inducing localized precipitation of surface proteins and tissue shrinkage of mucous membranes).
Chemical Groups:
- Pyrogallol derivatives: E.g., Tannic acid.
- Pyrocatechol derivatives: E.g., Catechu (Kattha).
Gums:
Complex hydrophilic polysaccharides naturally secreted as protective exudates by various trees and plants (e.g., Gum acacia from Acacia trees, and Gum tragacanth from Astragalus species).
Pharmacological Action: Possess zero intrinsic pharmacological or therapeutic activity.
Pharmaceutical Application: Exclusively utilized as inert physical vehicles, emulsifiers, and suspending agents to suspend and solubilize insoluble medicinal compounds.
Oils:
Liquid fatty acid glycerides possessing high calorific density, categorized into three distinct varieties:
- Volatile Oils (Essential or Aromatic Oils): Highly volatile liquids characterized by intense, distinctive fragrances; utilized as aromatic flavoring agents (e.g., Eucalyptus oil, Clove oil). An alkaline solution containing volatile oils is termed an essence, whereas an alcoholic formulation is designated a spirit.
- Fixed Oils: Non-volatile esters formed of glycerol coupled with long-chain fatty acids (including palmitic acid, stearic acid, oleic acid, and chaulmoogric/cholic acid), along with essential fatty acids such as linolenic acid () and linoleic acid (). They react with alkalis to undergo saponification and form chemical soaps/salts. Sourced via:
- Vegetable Origin: Olive oil, castor oil, groundnut (peanut) oil.
- Animal Origin: Cod liver/fish oil.
- Mineral Oils: Pure hydrocarbons obtained industrially via the fractional distillation of crude petroleum (e.g., liquid paraffin, soft paraffin, and hard paraffin); biologically inert and non-absorbable, they are utilized as vehicle bases for ointments and mechanical laxatives.
Principles of Pharmacokinetics and Membrane Passage
- Overview of Pharmacokinetics (PK):
- Definition: Etymologically derived from Pharmakon (drug) and Kinesis (movement). Defined operationally as "what the body does to the drug."
- The ADME Framework: A sequential four-stage process regulating drug movement inside biological systems:
- A: Absorption (the critical initial step determining systemic entry).
- D: Distribution.
- M: Metabolism (Biotransformation).
- E: Excretion.
- Functional Division of ADME:
- Placement within the body: Governed exclusively by the combination of Absorption and Distribution.
- Elimination from the body: Governed exclusively by the combination of Metabolism and Excretion.

Mechanisms of Transmembrane Transport:
Biological membranes consist of a dynamic phospholipid bilayer punctuated with integral membrane proteins, aqueous protein pores, and carrier channels.
1. Simple Diffusion (Passive Diffusion):
Quantitatively the most important physiological pathway for xenobiotic passage across cell membranes.
Movement occurs strictly along the concentration gradient from an area of higher concentration to lower concentration ("downhill movement").
Energetics: Completely energy-independent ( required).
Kinetics: A non-saturable process governed by Fick's first law.
Physical Requirement: Requires the drug molecule to exist in an uncharged, lipid-soluble state dissolved in the surrounding aqueous phase.
2. Filtration:
The bulk convective passage of dissolved drug molecules through microscopic aqueous pores or intercellular channels across the membrane.
Molecular Size Cut-Off: Permits passage only of small polar or non-polar molecules with molecular weights ranging between and .
Driving Force: Established by trans-membrane hydrostatic pressure or osmotic pressure differentials dragging water molecules (solvent drag).
Energetics: Completely energy-independent.
Examples: Renal glomerular filtration of polar molecules, and transcapillary passage of aminoglycosides and -lactam antibiotics.

3. Active Transport:
- Transmembrane translocation of solute molecules against an established concentration or electrical gradient ("uphill movement" from low to high concentration).
- Mechanism: The solute binds reversibly to a specialized membrane carrier protein on the external cell surface, forming a drug-carrier intermediate that translocates across the membrane.
- Energetics: Driven directly by energy released via the enzymatic hydrolysis of ATP.
- Kinetics: A saturable mechanism exhibiting a transport maximum (); subject to competitive and non-competitive inhibition by structural analogs.
- Biological Significance: Highly selective system restricted to specific sites for moving large, polar, hydrophilic molecules and biological ions (, , glucose, amino acids).
- Classifications:
- Primary Active Transport: Directly couples ATP hydrolysis to solute translocation (e.g., pump, which pumps out and brings into the cell).
- Secondary Active Transport: Driven by the electrochemical potential difference generated by primary ion pumps:
- Co-transport (Symport): Solute and driving ion move in identical directions (e.g., co-transport of glucose and amino acids in the intestinal brush border epithelium).
- Counter-transport (Antiport): Solute and driving ion move in opposing directions across the membrane (e.g., antiport exchanger).
4. Facilitated Diffusion:
- Carrier-mediated transport system that facilitates the downhill migration of solutes from high to low concentration.
- Energetics: Does not expend cellular energy ( consumption).
- Kinetics: Slower than simple diffusion at very high concentrations because it is a saturable process limited by carrier availability.
- Mechanism: Operates via a uniport mechanism, transporting only a single substrate molecule per conformational turnover.
- Examples: Entry of glucose into erythrocytes via GLUT-1 transporters, and intestinal absorption of Vitamin .
5. Pinocytosis (Fluid-Phase Endocytosis / "Cell Drinking"):
Membrane internalization process wherein the cell invaginates its outer membrane to engulf microscopic extracellular fluid droplets containing dissolved macromolecules, pinching off to form intracellular pinocytotic vesicles.
Examples: Cellular assimilation of fat-soluble vitamins (A, D, E, K) and macromolecular peptide hormones such as insulin.
Multidrug Efflux Systems:
Efflux Pumps: Specialized ATP-binding cassette (ABC) transmembrane transporter proteins that actively pump xenobiotics, toxins, and drugs out of the cytoplasm back into the extracellular environment, drastically lowering intracellular concentrations and reducing clinical drug efficacy.
Physiological Role: Protection of sensitive cells and tissues (such as the brain, liver, and testes) from xenobiotics and toxic end products.
Pathology & Resistance: Overexpression on malignant cancer cells or pathogenic microbes induces multidrug resistance (MDR).
Prominent Efflux Transporters:
- P-glycoprotein (P-gp / MDR1).
- Multidrug Resistance-Associated Proteins (MRPs).
- Breast Cancer Resistance Protein (BCRP).
Efflux Inhibitors: Chemical agents that selectively inhibit or block the action of efflux pumps, thereby elevating intracellular drug accumulation and restoring therapeutic sensitivity (e.g., Verapamil, Cyclosporine).
Drug Absorption and the pH-Partition Hypothesis
Mechanics of Absorption:
- Definition: The rate and extent of translocation of unchanged active drug from its site of administration into systemic blood circulation.
- Physiological Factors Dictating Absorption:
- Route of administration.
- Specific dosage formulation.
- Physicochemical parameters of the molecule.
- Drug concentration and administering volume.
- Local vascular perfusion at the administration site.
- Total surface area of the absorptive membrane.
The pH-Partition Hypothesis (Henderson-Hasselbalch Relationship):
- Biological fluids display distinct physiological pH gradients:
- Blood pH: Approximately .
- Gastric juice pH: Approximately .
- Intestinal lumen pH: Approximately .
- Electrolyte Nature: The vast majority of drugs are either weak organic acids or weak organic bases; very few are strong acids or strong bases.
- Ionization Equilibrium: Drugs exist in solution as an equilibrium mixture of un-ionized (lipid-soluble, neutral, highly diffusible) and ionized (lipid-insoluble, charged, polar, poorly diffusible) forms.
- The Principle: Only the un-ionized, lipid-soluble fraction diffuses across lipophilic biological cell membranes.
Mathematical Formulations (Henderson-Hasselbalch Equations):
For Weakly Acidic Drugs:
Acidic drugs remain largely un-ionized and lipophilic in acidic media (); thus, acidic drugs are preferentially absorbed from acidic environments such as the stomach.
Worked Numerical Problem from Transcript: (Result: For every ionized molecule, there are un-ionized molecules available for rapid membrane absorption).
For Weakly Basic Drugs:
Basic drugs remain largely un-ionized and lipophilic in alkaline environments (); hence, basic drugs are preferentially absorbed in the small intestine.
Worked Numerical Problem from Transcript: (Result: The drug is almost completely ionized in an acidic medium, precluding significant gastric absorption).
Caveat & Exception: The Henderson-Hasselbalch equation applies strictly to weak acids and weak bases. Strong acids and strong bases ionize completely across all physiological pH ranges, showing zero pH-dependent partitioning.
Routes of Drug Administration
Technique and Physiological Determinants:
- Defined as the anatomical path or method utilized to deliver an exogenous chemical compound into the body.
- The selection of route directly influences the onset of drug action, the overall duration of effect, therapeutic intensity, and the entire ADME profile.
Broad Classification of Routes:
- Oral / Enteral Route: Passage through the gastrointestinal tract.
- Parenteral Route: Routes bypassing the intestine entirely (e.g., IV, IM, SC, IP).
- Inhalation / Pulmonary Route: Direct absorption across the respiratory tree.
- Topical / Local Route: Direct superficial application to body surfaces or localized tissues.
Factors Dictating Route Selection:
- Lipid Solubility: Highly lipid-soluble drugs are capable of rapid absorption via virtually all physiological routes.
- Physical Form & Water Solubility: Water-insoluble suspensions and oily preparations must never be administered intravenously due to embolism risks; they must be given intramuscularly.
- Chemical Stability in GIT: Peptide hormones (e.g., insulin) and acid-labile drugs are rapidly destroyed by gastric acid and proteolytic enzymes, rendering oral delivery ineffective.
- Clinical Urgency: Acute emergency resuscitation excludes slow oral or subcutaneous routes, requiring immediate intravenous access.
- Site of Pathology: Superficial cutaneous infections require localized topical therapy, avoiding systemic toxicity.
- Patient State: Unconscious, vomiting, or seizing patients cannot receive oral medications.
- Differential Drug Action Example ():
- Administered Intravenously (IV): Acts on the neuromuscular junction and CNS to induce deep muscle relaxation and sedation.
- Administered Orally: Acts as an osmotic purgative/cathartic inside the gut lumen, drawing water into the bowel to cause fecal evacuation.
Detailed Profiles of Individual Routes:
1. Oral (Enteral) Route:
The oldest, safest, most economical, and most universally utilized mode of administration.
Timing relative to food: Drugs requiring rapid systemic absorption should be taken on an empty stomach; drugs that irritate the gastric mucosa must be ingested directly after meals.
Advantages: High safety profile, non-invasive, inexpensive, self-administrable, ideal for managing gastrointestinal infections and intestinal helminths.
Disadvantages: Slow onset of action; entirely unsuitable for acute emergencies, uncooperative/unconscious animals, or vomiting patients; destroyed by digestive enzymes; subject to extensive first-pass hepatic metabolism. In ruminants, oral delivery is generally unsuitable for systemic targets because the vast microbial and fluid volume of the rumen dilutes or metabolically inactivates active ingredients; liquid oral drenching carries high risks of fatal aspiration pneumonia.
2. Intravenous (IV) Route:
Involves injecting drugs directly into superficial, easily accessible veins.
Advantages: Grants immediate systemic bioavailability; ultra-fast onset of action (); life-saving in medical emergencies; permits continuous infusion of large volumes; tolerates hypertonic and irritating substances because blood flow dilutes the drug rapidly.
Disadvantages: High clinical risk because delicate vital organs (heart, brain) are instantaneously exposed to peak drug concentrations; non-reversible (once injected, drug cannot be recalled); requires strict aseptic technique and skilled personnel; completely contraindicated for insoluble micro-suspensions and oily vehicles (risk of fat or particle embolism); rapid elimination leads to short therapeutic duration.
3. Intramuscular (IM) Route:
Involves deep injection into large skeletal muscle masses.
Advantages: Technically simpler than IV; tolerates mild chemical irritants; provides longer therapeutic duration than IV due to depot absorption; optimal route for wild, intractable, furious, or zoo animals via remote darting.
Disadvantages: Cannot accommodate massive fluid volumes; improper injection technique risks severe mechanical nerve damage (e.g., sciatic nerve palsy) or vessel laceration; repeated deep injections induce localized muscle necrosis and sterile abscesses.
Remote Injection Darting: Specialized tranquilization technique using a compressed gas or powder rifle to deliver sedative-loaded darts into wild or unmanageable animals.
4. Subcutaneous (SC) Route:
Involves depositing the drug solution into loose subcutaneous connective tissue under the skin.
Advantages: Moderate-to-large volumes of non-irritating solutions can be accommodated; produces a slow onset paired with a long, continuous duration of action; ideal for routine vaccine administration and slow-release depots (e.g., insulin).
Disadvantages: Highly irritating chemical agents are contraindicated as they cause localized tissue necrosis, sloughing, severe pain, and sterile abscesses; poorly absorbed in hypovolemic or shock states with peripheral vasoconstriction.
5. Intraperitoneal (IP) Route:
Injection directly through the abdominal wall into the peritoneal cavity.
Advantages: Rapid systemic absorption across the large peritoneal surface area; accommodates large fluid volumes; valuable in neonatal resuscitation and small laboratory rodents (mice, rats).
Disadvantages: Accidental puncture of internal viscera; irritant drugs induce peritonitis and fibrous adhesions.
6. Inhalation (Pulmonary) Route:
Delivery of volatile liquids, gases, and fine aerosols directly via inhalation through the nasal passages and bronchial tree.
Advantages: Ultra-fast onset of action due to the vast surface area and capillary perfusion of pulmonary alveoli; completely bypasses intestinal and hepatic first-pass metabolism.
Disadvantages: Requires complex delivery apparatus (vaporizers, nebulizers); volatile irritants induce bronchospasm and coughing; fine dosing titration is difficult.
7. Specialized Regional Parenteral Routes:
Intra-arterial: Direct injection into a supplying artery; reserved primarily for targeted delivery of antineoplastic agents to localized neoplasms or diagnostic contrast imaging.
Intrathecal: Injection directly into the subarachnoid space (between arachnoid and pia mater) into the cerebrospinal fluid (CSF); utilized to bypass the blood-brain barrier for spinal anaesthesia and meningitis management.
Epidural: Injection into the epidural space of the spinal canal outside the dura mater; in cattle and horses, commonly administered at the intervertebral junction between the and coccygeal vertebrae to induce regional caudal anaesthesia for obstetrical manipulations.
Intramedullary: Injection into the vascular medullary cavity of long bones (bone marrow); used for rapid fluid and blood transfusions in collapsed pediatric patients when peripheral veins are unreachable.
Intracardiac: Direct emergency injection into the chambers or myocardium of the heart (e.g., epinephrine during cardiac arrest).
Intradermal: Injection into the vascular dermis layer of the skin (e.g., diagnostic tuberculin testing, allergy tests).
Intra-articular: Injection into synovial joint spaces (e.g., anti-inflammatory steroids for severe arthritis).
Intratracheal: Direct injection into the lumen of the trachea to treat localized pulmonary pathology or deliver emergency respiratory therapeutics.
8. Topical and Mucosal Administration:
Direct surface application to cutaneous tissue or mucous membranes:
- Cutaneous Surface: Ointments, creams, and lotions applied to the skin.
- Sublingual & Buccal: Formulations held under the tongue or against the cheek pouch mucosa; provides rapid absorption directly into the superior vena cava, completely bypassing hepatic first-pass metabolism (e.g., Nitroglycerin for acute angina pain).
- Intranasal: Medicated nasal sprays for localized mucosal action.
- Intraocular: Topical liquid eye drops for ocular conditions.
- Intramammary: Infusion cannulas inserted via the teat canal to clear mastitis infections.
- Local Infiltration: Subcutaneous infiltration of local anaesthetic agents (e.g., lidocaine) surrounding a surgical field.
- Per-Rectal: Suppositories and enemas utilized for systemic or localized effects; ideal in actively vomiting or unconscious patients; partially avoids hepatic first-pass metabolism.
Dynamics of Drug Distribution and Protein Binding
Mechanisms of Tissue Distribution:
- Definition: The reversible transfer of an absorbed drug between the intravascular systemic blood compartment and peripheral extravascular tissues, interstitial fluids, and cellular targets.
- Perfusion Hierarchy: Drugs distribute most rapidly to tissues with high capillary perfusion rates:
- Organ: Liver.
- Organ: Heart.
- Organ: Kidneys.
- Organ: Skeletal muscle.
- Subsequent sites: Adipose tissue, skin, and poorly perfused cortical bone.
- Determinants of Drug Distribution: Local tissue perfusion, lipid solubility of the compound, plasma protein binding affinity, tissue-specific barriers, and physiological states (age, pregnancy, body composition).
Plasma Protein Binding (PPB):
- Circulating drugs exist in a dynamic chemical equilibrium between two distinct physical fractions:
- Unbound (Free) Drug Fraction: Pharmacologically active, capable of diffusing across capillary walls, interacting with cellular receptors, and undergoing metabolic biotransformation and renal glomerular filtration.
- Bound Drug Fraction: Pharmacologically inactive, bound reversibly to plasma proteins (such as albumin and globulins). Because of its large molecular size, the drug-protein complex cannot diffuse across capillary membranes, cannot interact with receptors, and is shielded from glomerular filtration and hepatic metabolism.
- Binding Specificity:
- Acidic Drugs: Bind predominantly to plasma Albumin (e.g., Aspirin, Phenylbutazone, Warfarin).
- Basic Drugs: Bind predominantly to -acid glycoprotein (e.g., Lidocaine).
- Clinical Profiles:
- High Protein-Bound Drugs: Act as a circulating drug reservoir; exhibit a prolonged elimination half-life (), slow onset, long duration of action, low volume of distribution (), and narrow therapeutic window. Co-administration of a second highly bound drug can displace the first, raising free drug concentrations to toxic levels.
- Examples of Highly Bound Drugs: Quinidine, Digitoxin, Ketamine, Phenytoin, Phenylbutazone, Warfarin.
- Low Protein-Bound Drugs: Display rapid clearance, short half-lives, wide distribution into peripheral tissue compartments, and faster onset of therapeutic response.
- Examples of Low Bound Drugs: Enrofloxacin, Chloramphenicol, Morphine, Paracetamol.
Physiological Distribution Barriers:
- Specialized anatomical boundaries that restrict drug penetration:
- Blood-Brain Barrier (BBB): Continuous capillary endothelial tight junctions lacking fenestrations, surrounded by perivascular astrocyte end-feet and active efflux transporters; strictly limits entry to small, highly lipophilic uncharged compounds.
- Blood-Cerebrospinal Fluid Barrier (Blood-CSF Barrier).
- Placental Barrier: Separates maternal and fetal circulations; allows lipophilic drugs to cross, presenting teratogenic risks to the fetus.
Drug Biotransformation: Phase I Reactions
Nature of Biotransformation:
- Definition: The enzyme-catalyzed chemical alteration of drugs and foreign compounds (xenobiotics) occurring inside the body.
- Biological Objective: Converts lipophilic non-polar chemical compounds into hydrophilic, polar, water-soluble metabolites to facilitate excretion via the kidneys (urine) or liver (bile), simultaneously neutralizing biological toxicity.
- Sites of Metabolism:
- Primary Hepatic Site: The Liver (smooth endoplasmic reticulum and cytosol of hepatocytes).
- Extra-Hepatic Sites: Kidneys, intestinal mucosa, lungs, skin, and blood plasma.
- Metabolizing Enzymes:
- Microsomal Enzymes: Membrane-bound enzymes located in the lipid bilayer of the smooth endoplasmic reticulum (SER) of hepatocytes (e.g., CYP450 monooxygenases, glucuronyl transferases).
- Non-Microsomal Enzymes: Soluble enzymes situated in the cytoplasm, mitochondria, and extracellular plasma (e.g., esterases, amidases, dehydrogenases).
Metabolic Fates of Drugs:
- 1. Inactivation (Pharmacological Inactivation): An active therapeutic drug is converted into an inactive or less active metabolite:
- Paracetamol is converted into inactive glucuronide and sulphate conjugates.
- Morphine is biotransformed into Morphine-3-glucuronide (M3G, inactive) alongside Morphine-6-glucuronide (M6G, retains potent analgesic activity).
- 2. Bioactivation / Toxicological Activation: An active drug is converted into a more potent or toxic metabolite:
- Codeine is converted into Morphine (enhanced analgesia).
- Malathion (organophosphate insecticide) is converted into Malaoxon (neurotoxicant).
- Parathion is bioactivated into Paraoxon.
- Halothane is converted into Trifluoroacetic acid (hepatotoxic intermediate).
- 3. Prodrug Activation: A pharmacologically inert compound (prodrug) requires metabolic conversion in vivo to yield its active form:
- Levodopa is converted into Dopamine.
- Bacampicillin is converted into Ampicillin.
- Prednisone is converted into Prednisolone.
- Phenacetin is converted into Paracetamol.
- 4. Active Drug to Active Metabolite (Altered or Retained Profile):
- Altered Therapeutic Class: Iproniazid (antidepressant) is converted into Isoniazid (antitubercular agent).
- Retained Therapeutic Class: Digitoxin is converted to Digoxin; Diazepam to Nordiazepam; Phenylbutazone to Oxyphenbutazone.
Phase I (Functionalization / Non-Synthetic) Pathways:
- Phase I introduces, exposes, or unmasks reactive, polar functional groups (, , , ) on the drug molecule, rendering it more water-soluble and preparing it for Phase II conjugation.
- 1. Oxidation: Addition of oxygen or electronegative radicals, or removal of hydrogen/electrons.
- Microsomal Oxidation:
- Performed by the Mixed Function Oxidase (MFO) or Monooxygenase multienzyme system bound to the hepatic smooth endoplasmic reticulum.
- MFO Components: Cytochrome P450 (CYP450), NADPH, NADPH-cytochrome P450 reductase, and molecular oxygen ().
- Cytochrome P450 (CYP450): A superfamily of heme-proteins that absorb monochromatic light at a wavelength of . Responsible for approximately of total hepatic drug metabolism.
- Dominant Isoenzymes: CYP3A4 and CYP2D6 metabolize the largest proportion of clinical drugs, accounting for over of all hepatic enzymatic oxidations.
- Non-Microsomal Oxidation:
- Occurs in extra-microsomal sites (cytosol, mitochondria, plasma):
- Alcohol dehydrogenase: Oxidizes alcohols to aldehydes.
- Aldehyde dehydrogenase: Oxidizes aldehydes to carboxylic acids.
- Xanthine oxidase: Metabolizes methylxanthines (caffeine, theophylline, theobromine) which function as CNS stimulants.
- Dehalogenation: Splitting of halogen atoms from compounds (e.g., chloral hydrate).
- 2. Reduction: Addition of hydrogen/electrons, or removal of oxygen, forming polar hydroxyl () or amino () groups:
- Azo Reduction: Reduction of azo linkages (e.g., the azo dye Prontosil is reduced to active Sulphanilamide).
- Nitro Reduction: Reduction of nitro groups (e.g., Chloramphenicol).
- Carbonyl Reduction: Reduction of aldehydes/ketones to alcohols (e.g., Chloral hydrate).
- 3. Hydrolysis: Cleavage of drug chemical bonds accompanied by the addition of water, occurring at ester, ether, amide, and hydrazide bonds via esterases and amidases (e.g., choline esters such as acetylcholine, procaine, lidocaine, and catecholamines).
Drug Biotransformation: Phase II Conjugation Pathways
Nature of Phase II (Synthetic / Conjugation) Reactions:
- Involves the enzymatic coupling of an endogenous polar biomolecule (supplied by host liver cells) to a parent drug or its Phase I metabolite.
- Yields high-molecular-weight, highly ionized, hydrophilic conjugates that are devoid of pharmacological activity and rapidly excreted via urine or bile.
- Excretion Pathway: High-molecular-weight conjugates are preferentially secreted into the bile and eliminated in feces; lower-molecular-weight conjugates are filtered or secreted into urine.
Individual Conjugation Pathways:
1. Glucuronidation (Conjugation with Glucuronic Acid):
Quantitatively the most common and important Phase II pathway across mammalian species.
Biochemical Mechanism: The drug molecule couples with active Uridine diphosphate glucuronic acid (UDPGA), catalyzed by the microsomal enzyme UDP-glucuronosyltransferase (UGT) located in the hepatic smooth endoplasmic reticulum, yielding a water-soluble glucuronide conjugate excreted in urine.
Substrates: Morphine, Paracetamol, Chloramphenicol.
Critical Species Deficiencies: The glucuronyl transferase enzyme is congenitally absent or deficient in Cats and Fish.
Clinical Implication: Cats are uniquely susceptible to fatal Paracetamol toxicity because they cannot form paracetamol-glucuronide, forcing metabolism through minor pathways that generate toxic reactive intermediates.
2. Glutathione Conjugation:
Serves as a primary protective mechanism against toxic electrophilic intermediates.
Biochemical Mechanism: Catalyzed by Glutathione S-transferase; the reactive intermediate binds the nucleophilic sulfhydryl group of glutathione. The conjugate is subsequently degraded by peptidases into a mercapturic acid conjugate, which is excreted via urine, or eliminated directly via bile into feces.
Substrates: Reactive epoxides, quinones, and the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite of paracetamol.
Paracetamol Metabolism: Undergoes both glucuronidation and glutathione detoxification simultaneously.
3. Sulphate Conjugation (Sulpho-Conjugation):
Catalyzed by cytosolic (non-microsomal) sulphotransferases.
Biochemical Mechanism: The drug combines with the active sulfate donor 3'-phosphoadenosine-5'-phosphosulphate (PAPS):
Comparative Biology: Less prominent in most mammals, but serves as a compensatory primary conjugation route in Cats and Pigs.
Substrates: Chloramphenicol, phenolic steroids, and salbutamol.
4. Acetylation (Conjugation with Acetate):
A critical pathway for drugs containing free primary aliphatic or aromatic amino groups ().
Biochemical Mechanism: Catalyzed by N-acetyltransferase, utilizing Acetyl-Coenzyme A (Acetyl-CoA) as the acetyl group donor.
Atypical Feature: Acetylation is not a true detoxification pathway because acetylated metabolites are often less water-soluble than the original parent compound, increasing precipitation risks in acidic urine.
Species Deficiency: Acetyltransferase enzymes are absent in Dogs and Foxes (Canidae).
Clinical Implication: In carnivores (which have naturally acidic urine), administration of sulphonamides leads to precipitation of insoluble crystals in renal tubules, causing crystalluria, hematuria, and renal failure.
Substrates: Histamine, Isoniazid, Sulphonamides.
5. Conjugation with Thiosulphate:
An enzymatic pathway specifically utilized for the biological detoxification of deadly cyanide ions.
Reaction Scheme: Catalyzed by the mitochondrial sulfurtransferase enzyme Rhodanese:
6. Methylation (Conjugation with Methyl Group):
Quantitatively minor for exogenous synthetic drugs, but crucial for the synthesis, regulation, and degradation of endogenous biogenic amines.
Mechanism: Catalyzed by specific methyltransferases using S-adenosylmethionine (SAM) as the methyl group donor.
Substrates: Epinephrine, Norepinephrine, Histamine, Nicotine.
7. Amino Acid Conjugation:
Conjugation of carboxylic acid-containing drugs with endogenous amino acids:
- Glycine Conjugation: Predominant in common domestic animals and mammals (e.g., salicylic acid converts to salicyluric acid; cholic acid forms glycocholic acid).
- Glutamine Conjugation: Characteristic of humans and primates.
- Ornithine Conjugation: Characteristic of avian species/birds.
First-Pass Metabolism and Clinical Pharmacodynamics
First-Pass Hepatic Metabolism (Presystemic Elimination):
- Definition: The metabolic degradation and clearance of an orally administered drug that occurs before the compound reaches the systemic arterial circulation.
- Anatomical Route: Oral ingestion Gastrointestinal lumen Absorption across intestinal mucosa (site of intestinal first-pass metabolism) Mesenteric veins Hepatic Portal Circulation First entry into the Liver (site of extensive hepatic first-pass metabolism) Systemic Venous/Arterial Circulation.
- Pharmacokinetic Consequence: Markedly degrades systemic drug bioavailability (). Drugs subject to profound first-pass clearance cannot be administered orally, or require substantially larger oral doses compared to parenteral doses to achieve equivalent plasma levels.
Antimicrobial and Clinical Parameters:
- Minimum Inhibitory Concentration (MIC): The lowest concentration of an antimicrobial agent that inhibits the visible in vitro growth of a specific bacterial pathogen.
- Sub-MIC Dosing: Administering antimicrobial doses that fail to exceed the MIC creates sub-inhibitory drug levels, selectively driving the emergence of Antimicrobial Resistance (AMR).
- Clinical Considerations in Dosing: Individualized drug selection, dosing, and route planning must factor in underlying patient pathology, including multiorgan failure, hepatic cirrhosis, renal insufficiency, physical trauma, and overall economic cost-benefit ratios.